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ABSTRACT 
Objectives: Chemotherapy-induced nausea and vomiting (CINV) are major adverse effects of cancer chemotherapy. Inadequate control CINV can 
have a significant negative impact on quality of life and can compromise adherence to chemotherapy treatment. The aim of this prospective clinical 
trial was to evaluate the antiemetic effect of ondansetrone combined with dcexamethasone against CINV produced by high and moderate 
emetogenic chemotherapy in Iraqi patients. 
Materials and methods: A prospective clinical trial was conducted. Patients completed 5-day daily diaries beginning on the day of single-day 
chemotherapy and for one to three chemotherapy cycles, the symptoms diary was designed to collect data regarding patient’s demographic 
characteristics, cancer type, chemotherapy regimen to patient receive ondansetrone combined with dexamethasone for the treatment of CINV.  
Results: A total of 52 patients were enrolled in this study, with age range of 18-63 year (41.4±17.3; Mean ±SD) of both sexes (57.7% male and 
42.3% female), 65.38 % of the patients classified as receiving high emetogenic chemotherapy, whereas 34.61% of the patients receiving moderate 
emetogenic chemotherapy. All the patients received ondansetrone combined with dcexamethasone for the treatment of CINV, the incidence of acute 
nausea in patients receiving high emetogenic chemotherapy (HEC) was 41.17% compared to 22.22% in patients receiving moderate emetogenic 
chemotherapy (MEC); The incidence percent of delayed nausea was 35.29% in patients receiving HEC compared to 22.22% in patients receiving 
MEC; the effect of administered antiemetics on the incidence of acute vomiting was 35.29% in patients receiving HEC compared to 22.22% in 
patients receiving MEC; unexpectedly, the incidence of delayed vomiting was only 11.76% in patients receiving HEC compared to 22.22% in patients 
receiving MEC. 
Conclusion: the results of this study demonstrate that administration of Ondansetrone combined with dexamethasone regimen against CINV 
produced accepted antiemtic level compared to data reported internationally; this study highlights the need for efficient translation of standard 
guidelines of antiemetic to clinical practice. 
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INTRODUCTION 
Chemotherapy-induced nausea and vomiting (CINV) are major 
adverse effects of cancer chemotherapy that can negatively affect a 
patient’s quality of life as well as adherence with scheduled chemo-
therapy, leading to delay or sometimes to discontinue potentially 
beneficial treatment regimens. If poorly controlled, these adverse 
effects can give rise to medical complications, including poor 
nutrition, weight loss, dehydration, and electrolyte imbalances that 
complicate cancer management (1). Therefore, control of CINV is a 
crucial factor in ensuring that patients undergoing cancer 
chemotherapy can get the full benefit of therapy [2]. 
CINV can be classified under three distinct categories: acute onset, 
delayed onset, and anticipatory [3]. Acute CINV occurs within the 
first 24 hours following chemotherapy administration, whereas 
delayed CINV is defined as nausea and vomiting occurring after the 
first 24 hours and up to 5 days after chemotherapy is given. Delayed 
CINV can often be worse than acute symptoms because it is more 
likely to occur in a patient’s home, away from immediate medical 
assistance. Anticipatory CINV arises secondary to a history of poorly 
controlled nausea and vomiting during prior chemotherapy. A 
distinct clinical syndrome that may develop with administration of 
chemotherapy is known as breakthrough CINV that occurs when, 
despite the best prophylaxis used, the patient still experiences 
nausea and vomiting [4].  
The chemotherapeutic drugs have been classified into four emetic 
risk categories: high where 90% of patients will experience emesis 
without prophylaxis, moderate where 30%–90% of patients will 
experience emesis without prophylaxis, low where10%–30% of 
patients will experience emesis without prophylaxis, and minimal 
where10% of patients will experience emesis without prophylaxis 
[5]. Cisplatin represents the main example of a chemotherapeutic 
drug with a high emetogenic potential; doses greater than 50 mg/m2 
cause CINV in more than 90% of patients if no prophylaxis is used 
[6]. 
While several evidence-based consensus guidelines for preventing 
chemotherapy-induced nausea and vomiting (CINV) are published 
and regularly updated [7], studies suggest that the clinical uptake of 
antiemetic guidelines is often suboptimal, and CINV is a persistent 
problem for patients receiving chemotherapy [8]. Patients who 
experience CINV may be discouraged from completing their 
chemotherapy regimen; Moreover, patients with emesis may require 
emergency care or hospitalization, adding to the economic burden of 
cancer care [9].  
There are a number of shared principles in the major CINV 
guidelines from the American Society of Clinical Oncology (ASCO) 
[10], the Multinational Association for Supportive Care in Cancer 
(MASCC) [11], and the National Comprehensive Cancer Network 
(NCCN) [12]. These principles include the following: (1) the goal of 
CINV treatment is to prevent nausea and vomiting, not to treat them 
once they have occurred; (2) the risk period for CINV with MEC and 
HEC is at least 4 days, and patients must be protected for the entire 
risk period; (3) oral formulations and IV formulations of 5-HT3 
receptor antagonists are considered essentially equally effective; (4) 
selection of an antiemetic or antiemetic regimen should be based on 
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the emetic risk of chemotherapy, a patient’s prior antiemetic 
experience, and other patient factors; and (5) prophylactic 
antiemetic treatment should be used whenever the risk of CINV is 
10% or greater. 
Although there are many observational studies evaluating the 
effectiveness of different antiemetic regimens and the optimal 
means of implementing antiemetic guidelines in practice, but the 
effect of guideline adherence in preventing CINV still represents the 
substantial issue in this area. The aim of this prospective clinical trial 
was to evaluate the antiemetic effect of ondansetrone combined with 
dcexamethasone against CINV produced by high and moderate 
emetogenic chemotherapy in Iraqi patients. 
Patients and Methods 
A prospective clinical trial was conducted from April 2013 to 
November 2013 at the specialized oncology hospital in Baghdad-
Iraq; male and female outpatients (aged ≥ 18 years) who were 
scheduled to receive at least two cycles of single-day were eligible 
for inclusion in the study. Patients were excluded from the study if 
they received chronic systemic corticosteroid therapy, concurrent 
abdominal or pelvic radiation therapy; other key exclusion criteria 
were the presence of brain metastases or vomiting in the 24 h before 
chemotherapy. 
The study was approved by the scientific and ethics committee at 
Alkindy College of Medicine, University of Baghdad, and patients 
gave written informed consent. Patients completed 5-day daily 
diaries beginning on the day of single-day chemotherapy and for one 
to three chemotherapy 
cycles, the symptoms diary was designed to facilitate collection of 
data regarding patient’s demographic characteristics, cancer type, 
chemotherapy regimen, antiemetic medication prescribed in 
addition to incidence of CINV according to standard methods 
utilizing standard form (13); medical oncologists were asked to 
complete a questionnaire form regarding the incidence of nausea 
and emesis after administration of chemotherapy, assessments of 
the incidence rates of nausea and emesis were requested for the 
acute (Day 1) and delayed (Days 2–5,or ≥24hrs) phases were 
reported.  
Descriptive statistics were used to summarize patient demographics 
and study responses. Mean estimated incidence rates of nausea and 
emesis with 95% confidence intervals (95% CI) were reported. 
Results: 
The questionnaire was completed by one physician for 52 patients 
with age range of 18-63 year (41.4±17.3; Mean ±SD) of both sexes 
(57.7% male and 42.3% female), with duration of disease ranging 
from 1 -5years while the duration of chemotherapy treatment 
ranging between 1 -5 years. The main types of cancer were Non-
Hodgkin Lymphoma, brain tumor, Ca-rectum, Ca-bronchus, Ca-
ovary, testicular tumor, Hodgkin Lymphoma and other types, 65.38 
% of the patients classified as receiving high emetogenic 
chemotherapy were given cisplatin containing chemotherapy, 
whereas 34.61% of the patients receiving moderate emetogenic 
chemotherapy were given regimens containing Oxaliplatin, 
Carboplatin, Cyclophosphamide and Adriamycin, Table 1. 
* Emetogenic risk of chemotherapeutic agents classified according to 
the guidelines of the American Society of Clinical Oncology (14). 
Antiemetic therapy consistent with standard guidelines was used in 
the treatment of these patients. All the patients received 
ondansetrone combined with dcexamethasone for the treatment of 
CINV.  
Despite the administration of antiemetic therapy, the incidence of 
acute nausea in patients receiving high emetogenic chemotherapy 
(HEC) was 41.17% compared to 22.22% in patients receiving 
moderate emetogenic chemotherapy (MEC), figure 1. 
 
Table 1: Patients’ Details. 
Variable Details Value 
Age  
 
Range 18-63 (year) 




Male  57.7% 
Female  42.3% 
 





Brain tumor 19.23% 
Ca rectum 15.38% 
Ca bronchus 11.53% 
Ca ovary 11.53% 
Testicular tumor 7.69% 









Moderate emetogenic  
Chemotherapy 
34.61% 
Duration of disease 1 -5 years 
Duration of chemotherapy treatment 
 
1 -5 years 
 
 
Fig.1: Effect of Ondansetrone combined with dexamethasone on 
the incidence of acute nausea in patients receiving high 
emetogenic chemotherapy (HEC) and moderate emetogenic 
chemotherapy (MEC). 
The incidence percent of delayed nausea after administration of 
ondansetrone combined with dcexamethasone was 35.29% in 
patients receiving high emetogenic chemotherapy (HEC) compared 
to 22.22% in patients receiving moderate emetogenic chemotherapy 
(MEC), figure 2. 
 
Fig.2: Effect of Ondansetrone combined with dexamethasone on 
the incidence of delayed nausea in patients receiving high 
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The effect of administered antiemetics on the incidence of acute 
vomiting was 35.29% in patients receiving high emetogenic 
chemotherapy (HEC) compared to 22.22% in patients receiving 
moderate emetogenic chemotherapy (MEC), figure 3. 
Unexpectedly, the incidence of delayed vomiting (the most 
important entity among CINV that face both patient and clinicians) 
was only 11.76% in patients receiving high emetogenic 
chemotherapy (HEC) compared to 22.22% in patients receiving 
moderate emetogenic chemotherapy (MEC), figure 4. 
 
Fig.3: Effect of Ondansetrone combined with dexamethasone on 
the incidence of acute vomiting in patients receiving high 




Fig.4: Effect of Ondansetrone combined with dexamethasone on 
the incidence of delayed vomiting in patients receiving high 
emetogenic chemotherapy (HEC) and moderate emetogenic 
chemotherapy (MEC). 
DISCUSSION 
Pharmacological interventions for CINV are recommended based on 
the type of nausea and/or vomiting and the emetogenicity of the 
chemotherapy. Treatment guidelines for the prevention of acute and 
delayed CINV have been developed by a number of cancer societies 
ASCO (15), MASCC/ESMO (16) and NCCN (17). 
For acute emesis, the updated MASCC/ESMO guidelines recommend 
triple therapy with a 5-HT3-Receptor Antagonist, corticosteroid 
(dexamethasone) and NK1- Receptor Antagonist for HEC regimens. 
Triple therapy is also recommended for anthracycline plus 
cyclophosphamide containing regimens. In other MEC regimens, the 
updated MASCC/ESMO guidelines recommend the double therapy 
with a 5-HT3-RA (palonosetron preferred) and a corticosteroid 
(dexamethasone). For delayed emesis, the updated MASCC/ESMO 
guidelines recommend in patients receiving HEC, a combination of a 
corticosteroid (dexamethasone) and NK1-RA. For AC-based regimen, 
aprepitant as a monotherapy should be given. In other MEC 
regimens, a corticosteroid (dexamethasone) or a 5-HT3- RA 
alternatively, when palonosetron was not part of the primary 
prophylactic treatment, are the agents of choice (18).  
Despite the availability of treatment guidelines, there is evidence 
that adherence to and implementation of treatment 
recommendations are less than optimal (19) and that actual clinical 
practice is lagging behind current guidelines for the use of 
prophylactic antiemetics (20). 
The 5-HT3RAs are without doubt the most effective antiemetics in 
the prophylaxis of acute CINV. The different 5-HT3RAs appear to be 
interchangeable. The lowest fully effective once daily dose for each 
agent should be used. Dexamethasone plays a major role in the 
prevention of acute and delayed CINV and is an integral component 
of almost all antiemetic regimens (21).  
The results of this study showed that although there is a good 
adherence to the current guidelines for antiemetic use, 63.39% of 
patients experience acute nausea post chemotherapy treatment 
(41.17% for HEC and 22.22% for MEC); moreover, 57.51% of 
patients experience delayed nausea post chemotherapy treatment 
(35.29% for HEC and 22.22% for MEC type), furthermore, results of 
this study reported that the incidence of acute vomiting was 57.51% 
(35.29% for HEC and 22.22% for MEC type), compared to the 
incidence of delayed vomiting which is 33.98% (11.76% for HEC and 
22.22% for MEC type); although the incidence of delayed vomiting 
due to administration of HEC which is the most important target was 
lower than that produced due administration of MEC, the results 
indicate that CINV remained a substantial problem for patients 
receiving chemotherapy, these results are comparable with other 
results obtained by different studies (22,23).  
In conclusion, the results of this study demonstrate that 
administration of Ondansetrone combined with dexamethasone 
regimen against CINV produced accepted antiemtic level compared 
to data reported internationally; this study highlights the need for 
efficient translation of standard guidelines of antiemetic to clinical 
practice.  
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